[A18-39] Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08
Last updated 03.08.2018
Project no.:
A18-39
Commission:
Commission awarded on 13.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Cystic fibrosis (CF) in 6 to 11 year old children who are homozygous for the F508del mutation in the CFTR gene
Result of dossier assessment:
Conclusion of dossier assessment A18-08 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-08 | Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.